Yale Cardiovascular Medicine Grand Rounds - The Future of Cardiac Death and MI Prevention: Detection and Treatment of Vulnerable Plaque.
October 02, 2026Dr. Henry Cabin Honorary Lecture
Information
- ID
- 14548
- To Cite
- DCA Citation Guide
Transcript
- 05:30Okay, everyone. I think we'll,
- 05:32go ahead and get started,
- 05:34since at least our guests
- 05:35of honor are seated,
- 05:38although there's a few people
- 05:39coming in getting lunch.
- 05:40First and foremost, I I
- 05:42wanna,
- 05:43welcome everyone,
- 05:44here,
- 05:46to our... The beginning of
- 05:47our grand rounds, program for
- 05:49this year
- 05:50and also to welcome,
- 05:52all the many people that
- 05:53are in our different watch
- 05:54parties across the state.
- 05:56And thanks again to our
- 05:58staff.
- 06:00Many are in the back.
- 06:01I won't embarrass them by
- 06:03naming them all for helping
- 06:04us coordinate,
- 06:06this,
- 06:07across, you know, all our
- 06:08hospitals and our locations,
- 06:11and to connect
- 06:13and feed people in all
- 06:14those locations as well, which
- 06:15is which has been a
- 06:16great,
- 06:17and and very well received.
- 06:18I also wanna take this
- 06:19opportunity to thank,
- 06:21Catherine,
- 06:23Hattie, and Philippe,
- 06:24for a really
- 06:26wonderful job in in helping
- 06:27coordinate this,
- 06:29CME activity
- 06:30and getting,
- 06:31a a tremendous
- 06:33panel of, speakers set up
- 06:34for this year.
- 06:36And and so,
- 06:38and and and we're very
- 06:39excited to have really
- 06:43incredibly important member of our
- 06:45cardiovascular community giving grand rounds
- 06:47today. But before I do
- 06:48that, let me just make
- 06:49a few announcements, and and
- 06:51I'll introduce Alexander to introduce
- 06:53Greg.
- 06:54So for everyone, just please
- 06:56get your CME
- 06:57credit.
- 06:59Let's see if that can
- 07:01go.
- 07:03Oh, it's not going.
- 07:07Okay. And that's just our
- 07:08disclosure statement.
- 07:10And this is,
- 07:13just some information. So maybe
- 07:15say a few words not
- 07:16to embarrass doctor Kavan who's
- 07:18in the audience,
- 07:19but just to,
- 07:20recognize the critically important
- 07:23impact he's had,
- 07:26at at this institution and
- 07:27our hospital
- 07:29over,
- 07:30I think more than...
- 07:32Aiming close to fifty years
- 07:34now almost.
- 07:36And so,
- 07:37Henry,
- 07:39did his
- 07:41undergraduate degree at Penn.
- 07:43He's from Great Neck originally
- 07:44for those who, don't know
- 07:46that, but I just sort
- 07:47of sort out a way
- 07:48in there. And, and then
- 07:50joined Yale the...
- 07:51As a medical student originally,
- 07:54and then, joined our residency
- 07:56at Yale New Haven Hospital.
- 07:59You know, he
- 08:01then took a sojourn
- 08:03to the NIH for several
- 08:04years where he was in
- 08:06the pathology branch of the
- 08:07NHLBI.
- 08:09And, his first papers were
- 08:10with Bill Roberts,
- 08:12looking at
- 08:13the impact of coronary artery
- 08:15disease,
- 08:16on aneurysmal formation
- 08:18and the intersection between the
- 08:20coronary anatomy and it's,
- 08:22and when it's blocked and
- 08:24aneurysm formation, which I think
- 08:25is always really wonderful to
- 08:27re... Review those papers,
- 08:29which I have,
- 08:30printed out in my, in
- 08:31my files.
- 08:32And then he came back
- 08:34to complete his cardiology fellowship
- 08:36and joined our faculty,
- 08:38I believe in in,
- 08:40in eighty
- 08:41two,
- 08:43and, and,
- 08:45really was,
- 08:47in so many different roles,
- 08:48a member of our... A
- 08:49a a critical member of
- 08:50our faculty rising
- 08:52within
- 08:54a little more than a
- 08:54decade to full professor
- 08:56and serving in in multiple
- 08:58different roles in our system
- 08:59as not only medical director
- 09:00of Yale New Haven
- 09:02Hospital Heart and Vascular Center,
- 09:03but as a vice chair
- 09:05for department in clinical affairs
- 09:06and then an interim chief,
- 09:08role, for several years, before,
- 09:11his his, becoming Emeritus in,
- 09:14in two thousand and one.
- 09:15So,
- 09:16thank you, Henry, for twenty
- 09:18twenty one. I'm sorry.
- 09:20Not to that one.
- 09:22Because you look really good
- 09:23if you became Emeritus in
- 09:24two thousand one.
- 09:26Anyway, thank you, Henry, for
- 09:27everything you've done for all
- 09:28of us. For me, you've
- 09:30been a a really great
- 09:31colleague when I joined,
- 09:33New City Institution and helped
- 09:34shepherd my my development. So,
- 09:36we we really use this
- 09:37opportunity to thank you and,
- 09:39and and bring a tremendous
- 09:41speaker to to to the
- 09:42campus on your behalf and
- 09:43and celebrate you. So with
- 09:45that, I'm gonna ask Alexandra
- 09:47to introduce our speaker.
- 09:54Okay. Well, welcome to our
- 09:56first grand rounds and our,
- 09:59Henry Caban lectureship. It's really
- 10:01great to see everybody in
- 10:02this room
- 10:04to honor
- 10:05our very own Henry Cabin,
- 10:06who spent much of his
- 10:08career
- 10:09building a premier interventional program
- 10:11right here at Yale. So
- 10:13thank you for your
- 10:14your work, your contributions.
- 10:16It's just wonderful to see
- 10:18you.
- 10:19That said, it gives me
- 10:21enormous pleasure to introduce our
- 10:22speaker today, doctor Greg Stone.
- 10:24So,
- 10:25Greg is professor of medicine
- 10:27and population health sciences
- 10:29at the Icahn School of
- 10:30Medicine at Mount Sinai in
- 10:32New York.
- 10:33And I suspect, I hope,
- 10:35many of you,
- 10:37took a quick look at
- 10:38his amazing CV that was
- 10:40circulated
- 10:41with, the invitation to come
- 10:43here, all six hundred pages
- 10:47of his CV. So I'm
- 10:48just gonna tell you, I'm
- 10:49not gonna,
- 10:51even begin to try and,
- 10:54summarize his CV here. It
- 10:56would take me till tonight.
- 10:58Simply, I wanna say that
- 11:00there are very, very few
- 11:02people
- 11:02in, our field that have
- 11:04had the profound impact
- 11:07that Greg has had on
- 11:08our guidelines
- 11:09and the way we practice
- 11:10cardiovascular medicine today.
- 11:13His contributions
- 11:15are nothing less than prolific.
- 11:17So based on his CV,
- 11:19he has a hundred and
- 11:21thirty multicenter
- 11:23randomized clinical trials
- 11:26that he has designed and
- 11:28conducted,
- 11:29and he has about two
- 11:31thousand
- 11:31peer reviewed manuscripts
- 11:33in the highest impact journals.
- 11:36It's no small feat.
- 11:39His trials have changed practice
- 11:41across virtually every domain of
- 11:44interventional cardiology.
- 11:46From acute myocardial infarction, I
- 11:49had the great privilege in
- 11:50my early career to be
- 11:51working with Greg on the
- 11:53Horizons AMI clinical study,
- 11:56vulnerable plaque. He's gonna be
- 11:57talking to us about that
- 11:59today, but it goes well
- 12:00beyond that. Antithrombotic
- 12:02therapy,
- 12:03drug eluting stents,
- 12:05invasive imaging,
- 12:07structural heart disease, mitral valve
- 12:09disease, and more recently,
- 12:11heart failure.
- 12:12And on that note, we're
- 12:14absolutely privileged to be,
- 12:16working very closely together with
- 12:18Greg,
- 12:19with Catherine and,
- 12:21Clark and Carlos Mena's leadership
- 12:24here at Yale
- 12:25in a, evaluating
- 12:27a pulmonary denervation
- 12:29therapy for patients with group
- 12:31two pulmonary hypertension. We're absolutely
- 12:34thrilled to be able to
- 12:35partner with you on that.
- 12:38I would
- 12:39characterize Greg as the consummate
- 12:42academic
- 12:43clinician.
- 12:44He's a masterful educator as
- 12:46we're gonna see and hear.
- 12:48His knowledge is
- 12:51nothing less than encyclopedic.
- 12:53His scientific rigor knows absolutely
- 12:57no bound,
- 12:58and he's
- 12:59got a relentless, and I
- 13:01mean relentless
- 13:03attention to detail.
- 13:05I'm gonna just wrap it
- 13:07up here. I don't wanna
- 13:08go on and on, but
- 13:09I just wanna say a
- 13:10few personal things. Greg has
- 13:12been an outstanding
- 13:14collaborator, mentor, and a dear
- 13:16friend to myself
- 13:18and so many in the
- 13:19field.
- 13:21And if you think about
- 13:22it with all the accomplishments
- 13:25that Greg has had,
- 13:27he's incredibly generous with his
- 13:29time. We're thrilled that you're
- 13:31here today to share your
- 13:32knowledge and teach our faculty.
- 13:34And he's just genuinely a
- 13:36wonderful,
- 13:37wonderful human being. So please
- 13:40join me in welcoming
- 13:41one of the truly
- 13:43transformative
- 13:44figures in modern interventional cardiology,
- 13:47doctor Greg Stone.
- 13:57Well, thank you, Alexander, for
- 13:59that beautiful introduction. And, yeah,
- 14:01Alexander and I go back
- 14:02a long way, and I'll
- 14:03I'll just tell everybody here
- 14:04you're very lucky to have
- 14:06her here at Yale.
- 14:07It's also really a pleasure
- 14:09to be here.
- 14:10My, daughter recently graduated,
- 14:12from the School of Public
- 14:14Health, so I'm
- 14:15no stranger to this campus.
- 14:17And, also, while I work
- 14:19at Mount Sinai Medical Center
- 14:20in New York City, I
- 14:21actually live in Greenwich, Connecticut.
- 14:22So I'm not gonna get
- 14:23any awards for being the
- 14:25farthest person who's come away
- 14:27for this year for your
- 14:28grand rounds for this talk.
- 14:30But it's gonna be really
- 14:31great to speak to you
- 14:32today about
- 14:33a new topic. It may
- 14:34be new to some of
- 14:35you. Let's see how I
- 14:37advance here.
- 14:39Oh, Keith. Okay. Great.
- 14:41And that's on a a
- 14:43new area, which is becoming
- 14:44really on a lot of
- 14:45people's radar screens,
- 14:47especially those of us who
- 14:48are interested in revascularization
- 14:50therapy. Because as I'm gonna
- 14:51show you, most of what
- 14:52we do when we revascularize
- 14:54patients, either with PCI or
- 14:56with surgery,
- 14:57really does not prolong life,
- 14:59and it does not prevent
- 15:00myocardial infarctions. It makes people
- 15:01feel better. But we're probably
- 15:03not getting the most out
- 15:05of these approaches. And and
- 15:06these are, you know, therapies
- 15:07that are done in up
- 15:08to a million people a
- 15:09year in the United States
- 15:11alone.
- 15:12And, as I'm gonna show
- 15:13you, we've really been focusing
- 15:15on the wrong areas of
- 15:16the coronary tree, And that's
- 15:18really hard to believe, but
- 15:19it's really true. So I'm
- 15:21gonna talk to you about
- 15:22today about the detection and
- 15:23treatment of vulnerable plaque because
- 15:24that's really where all the
- 15:26action is.
- 15:28So
- 15:29I like to really start
- 15:30with this slide. This was
- 15:31an incredible,
- 15:32article that was written by
- 15:34Betsy Nabel and Eugene Braunwald
- 15:36a number of years ago
- 15:37in the New England Journal,
- 15:38and they tried to relate
- 15:40the tremendous
- 15:41advances that have been made
- 15:42in reducing case fatality rates
- 15:44in in patients, with cardiovascular
- 15:46disease. And you could see
- 15:47from nineteen fifty to nineteen
- 15:49seventy, there was a very
- 15:50high case fatality rate. And
- 15:52then starting in nineteen seventy
- 15:53down through about two thousand
- 15:54and ten, there was this
- 15:56tremendous steady decline, about a
- 15:58seventy percent reduction,
- 16:00in mortality from heart disease.
- 16:02And they related to several
- 16:04of the seminal advances.
- 16:05And and several of these,
- 16:07obviously relate to prevention,
- 16:09but several are also due
- 16:10to the development, first of
- 16:11cardiac surgery and then of
- 16:13coronary angioplasty,
- 16:15and,
- 16:16then to the treatment of
- 16:17acute myocardial infarction, first with
- 16:19thrombolytic therapy and then with,
- 16:21primary angioplasty.
- 16:22And so it looks like
- 16:23this is just a huge
- 16:25success story for cardiology.
- 16:27And if you look, where
- 16:28we really make a difference
- 16:30is in our treatment in
- 16:31patients with heart attacks. In
- 16:33patients with STEMI,
- 16:35I was telling Eric earlier,
- 16:37we were involved in the
- 16:38very first trial, the PAIMI
- 16:39trial, which is really the
- 16:40one that, changed things, and
- 16:42that led to a total
- 16:43of twenty three randomized trials
- 16:45of primary PCA
- 16:46versus thrombolytic therapy in patients
- 16:48with ST segment elevation MI.
- 16:50And we showed that we
- 16:51clearly reduced mortality,
- 16:53reduced reinfortunes,
- 16:55eliminate essentially all the hemorrhagic
- 16:57strokes, so we reduce total
- 16:59stroke. People go home from
- 17:00the hospital earlier. They get
- 17:02better myocardial recovery, etcetera, etcetera.
- 17:04And that, I don't have
- 17:05to tell anybody here, has
- 17:06been probably the biggest success
- 17:08story and the... Where, as
- 17:10interventional cardiologists, we can make
- 17:11the biggest difference in patients'
- 17:13lives.
- 17:14The same is true in
- 17:15non ST segment elevation myocardial
- 17:17infarction,
- 17:18where, again, meta analysis have
- 17:20shown in about eighty four
- 17:21hundred patients that we reduce
- 17:22mortality and myocardial infarction.
- 17:26But still, despite all of
- 17:27this progress, cardiovascular disease is
- 17:30still what some would call
- 17:31a global pandemic.
- 17:32And this, you know, recent,
- 17:35compilation in The Lancet shows
- 17:36that still it is the
- 17:38number one cause of death
- 17:40around the world, responsible for
- 17:42about one third of all
- 17:44deaths in the, complete world,
- 17:46with ischemic heart disease being
- 17:48the number one cause of
- 17:49death, almost twenty million people
- 17:51per year.
- 17:52And if you look at
- 17:53what's going on in the
- 17:54United States, actually,
- 17:56despite all that progress that
- 17:58we've made, we've kind of
- 17:59stalled since about nineteen ten.
- 18:01And from nineteen ten to
- 18:02nineteen twenty five, the case
- 18:03fatality rates for heart disease
- 18:05are pretty flat. And in
- 18:07fact, given the, increasing age
- 18:09of the patient population and
- 18:11the increasing population, the, number
- 18:13of deaths from cardiovascular disease
- 18:15are actually increasing.
- 18:17So we've got a lot
- 18:18of work to do.
- 18:21So
- 18:22as successful as we've been
- 18:23in treating patients with acute
- 18:25coronary syndromes,
- 18:26we don't have the same
- 18:28impact on patients with chronic
- 18:29coronary syndromes.
- 18:31And I'll never forget when,
- 18:33the presentation of the COURAGE
- 18:34trial was,
- 18:36released at the American College
- 18:37of Cardiology a number of
- 18:38years ago by Bill Boden,
- 18:40the first big randomized trial
- 18:42of twenty two hundred and
- 18:43seventy patients or so. Chronic
- 18:45coronary syndromes,
- 18:46randomized their medical therapy versus
- 18:48PCI plus medical therapy. Absolutely
- 18:51no difference in the seven
- 18:52year rates of death, cardiovascular
- 18:54death, or myocardial infarction. And
- 18:56we all thought that something
- 18:57must have been done wrong,
- 18:58but it actually wasn't. This
- 19:00was true. It was then
- 19:01shown in the,
- 19:03subsequent berry studies and others.
- 19:06So we thought, okay. Maybe
- 19:07the problem was is that
- 19:08they're not enrolling high enough
- 19:10risk patients Because a lot
- 19:11of the patients didn't have
- 19:13ischemia in these trials, they
- 19:14just had anatomic disease.
- 19:16And, I had trained at
- 19:17Cedars Sinai Medical Center in
- 19:19Los Angeles for my general
- 19:20fellowship,
- 19:21and there was, this is
- 19:23one paper that... That's been
- 19:25probably quoted and downloaded ten
- 19:27thousand times.
- 19:28And in a non randomized
- 19:29fashion,
- 19:30they showed a relationship between
- 19:32the extent of quantitative ischemia
- 19:35of the left ventricle and
- 19:36outcomes.
- 19:37The more,
- 19:38myocardial ischemia there was, the
- 19:40greater the rates of myocardial
- 19:41infarction and cardiovascular death. And
- 19:43if patients who happened in
- 19:44a nonrandomized
- 19:45fashion to have gotten revascularization
- 19:47therapy compared to medical therapy,
- 19:49it seemed like the more
- 19:50ischemia you had, the better
- 19:52the response to revascularization.
- 19:54And when you got to
- 19:55about ten percent of the
- 19:57ventricle being ischemic, that seemed
- 19:59to be where revascularization,
- 20:01had a big advantage.
- 20:03So that led us to
- 20:04design the ischemia trial. And
- 20:06I was one of the
- 20:07co principal investigators along with
- 20:08Bob Harrington and, of course,
- 20:10Judy Hochman and Dave Marron.
- 20:12And we said, okay. Let's
- 20:13take chronic coronary syndromes,
- 20:15patients with at least ten
- 20:17percent myocardial ischemia,
- 20:19but who don't have a
- 20:20lot of symptoms, so they're
- 20:21not gonna all cross over.
- 20:23And let's randomize those patients
- 20:25to,
- 20:26either an angiographic strategy followed
- 20:28by revascularization
- 20:29with either PCI or CABG
- 20:31is appropriate, versus just conservative
- 20:33care, where you don't even
- 20:34do an angiogram. You don't
- 20:35even have to know what
- 20:36the coronary anatomy is.
- 20:38And this, of course, was
- 20:40the result of the ischemia
- 20:41trial, and this is very
- 20:42contemporary.
- 20:43And there was no overall
- 20:45reduction in cardiovascular
- 20:46death or myocardial infarction.
- 20:49There was a slight early
- 20:50risk of doing the procedures,
- 20:52not bad, but a little
- 20:53bit of an early risk.
- 20:54There was a little bit
- 20:55of a late benefit perhaps,
- 20:57but overall, no significant difference
- 21:00with follow-up to five years.
- 21:01And at the this year,
- 21:03we'll report the absolute final
- 21:05ten year, what we call
- 21:06ischemic extend follow-up,
- 21:08in this,
- 21:09trial as a late breaker.
- 21:12Now don't get me wrong.
- 21:14We do make people feel
- 21:15better
- 21:16by revascularizing
- 21:17with chronic coronary syndrome.
- 21:19And, the major secondary endpoint
- 21:21in this trial was the
- 21:22relief of angina,
- 21:23and I could show you
- 21:24this data cut in many,
- 21:25many ways. But there's a
- 21:27marked reduction in angina, either
- 21:29the absolute level of angina
- 21:30or becoming angina free and
- 21:32improve quality of life as
- 21:33measured by the SACS score
- 21:34in others. So we make
- 21:36people feel better. And the
- 21:37the patients who are having
- 21:38symptoms, the more symptoms they
- 21:40have, the more we're gonna
- 21:40make them feel better. But
- 21:42we don't make them live
- 21:43longer, and we don't prevent
- 21:45myocardial infarctions.
- 21:46And that's hard for,
- 21:48many general cardiologists, let alone
- 21:50interventionalists and cardiac surgeons to
- 21:52accept.
- 21:53There may be some exceptions,
- 21:55perhaps high grade left main
- 21:56disease. The old data suggested
- 21:58that, yes, surgery makes a
- 22:00difference there. Perhaps extensive disease
- 22:00with
- 22:03extensive disease with proximal AD
- 22:04involvement, but we don't even
- 22:05have great data on that
- 22:06to suggest that we're improving
- 22:08prognosis.
- 22:10And the reason, I think,
- 22:12is that we're really focusing
- 22:14on the wrong parts of
- 22:15the coronary tree.
- 22:17So this is the typical
- 22:18type of lesion that we're
- 22:19revascularizing
- 22:20in patients with chronic coronary
- 22:22syndromes. You see a long
- 22:23seventy five, eighty percent stenosis
- 22:25in the right coronary artery,
- 22:27and this is enough to
- 22:29invoke exercise induced ischemia so
- 22:31the patients will have angina,
- 22:33and dyspnea exertion, etcetera.
- 22:35But when you look at
- 22:36this lesion, pathologically,
- 22:38you see what's called... What
- 22:40I call garden variety atherosclerosis,
- 22:42which is pathologic interval thickening.
- 22:44Okay. This is a very
- 22:45stable, often fibrotic lesion,
- 22:48and it will, yes, constrict
- 22:50the lumen and therefore restrict
- 22:52blood flow,
- 22:54during stress or exercise,
- 22:56but it rarely goes on
- 22:58to fissure or thrombose and
- 23:00cause a myocardial infarction. This
- 23:02lesion could be stable for
- 23:03forty years.
- 23:06So I really got interested
- 23:07in this field from a
- 23:08study that came out,
- 23:10several decades ago,
- 23:12from the NHLBI
- 23:13dynamic registry.
- 23:15And they first published on
- 23:17thirty seven hundred patients that
- 23:18underwent PCI,
- 23:20and they actually
- 23:21found that six percent of
- 23:22those patients
- 23:24within one year
- 23:26developed an acute coronary syndrome,
- 23:28mostly acute myocardial infarction,
- 23:30at sites that were remote
- 23:32from any area that was
- 23:33intervened on. And this is,
- 23:35again, not such a great
- 23:36image, but from the original
- 23:37publication.
- 23:39A right coronary artery, and
- 23:40you can see very mild
- 23:41diffuse disease in the right.
- 23:43And that within one year,
- 23:44there's a new subtotal stenosis
- 23:46in that right coronary artery.
- 23:48And the mean plaque progression
- 23:50went very quickly from forty
- 23:51two percent to eighty four
- 23:52percent angiographically at a mean
- 23:54of five point two months.
- 23:56And this was kind of
- 23:57termed a vulnerable plaque. That
- 23:59is a plaque that you
- 24:00don't... Maybe not appreciate that
- 24:02it's such a severe lesion,
- 24:03but but it's the kind
- 24:04of lesion that places the
- 24:05patients at risk for future
- 24:07cardiovascular events.
- 24:09And there were multiple studies
- 24:10that then came out that
- 24:11showed that these plaques are...
- 24:13That that had a serial
- 24:14angiograms and showed that these
- 24:16plaques are very mild appearing
- 24:17angiographically.
- 24:18They're never the kind of
- 24:20plaques that we would do
- 24:20PCI on, and the surgeons
- 24:22would never bypass these kind
- 24:23of plaques. But the majority
- 24:25that that then close, they
- 24:27usually thrombose, and they either
- 24:29get a subtotal or a
- 24:30total occlusion,
- 24:32cause either sudden cardiac death,
- 24:33a STEMI or a non
- 24:35STEMI. Again, they go from
- 24:37very, very mild to very
- 24:39severe, very suddenly.
- 24:41So
- 24:42most of these plaques, when
- 24:44you look at them pathologically,
- 24:46are so called tikfas,
- 24:48thin capped fibroatheromas.
- 24:51And in contrast to that
- 24:52last pathologic image I showed
- 24:54you, these look very, very
- 24:55different. They have this very
- 24:57well formed necrotic core, which
- 24:59consists of cholesterol, cholesterol esters,
- 25:02and inflammatory
- 25:03cells, macrophages, and t lymphocytes.
- 25:05And there's a very thin
- 25:07fibrous cap separating this necrotic
- 25:09core from the lumen. And
- 25:11that thin fibers cap is
- 25:12very metabolically active. It's,
- 25:15infiltrated with macrophages.
- 25:16And when matrix metalloproteinases
- 25:19and other digestive enzymes get
- 25:20released, that fibrous cap can
- 25:22rupture.
- 25:23And that leads the necrotic
- 25:24cord to release its very
- 25:26prothrombotic
- 25:26contents, including tissue factor, and
- 25:29you suddenly
- 25:30can get a thrombotic occlusion.
- 25:32Now in this case, I
- 25:33showed you a tiktva, which
- 25:35was relatively obstructive.
- 25:36And some of these tiktva
- 25:37are obstructive,
- 25:39but probably about sixty percent
- 25:40of them are like this.
- 25:42Okay? They've got really a
- 25:43well preserved lumen, but there's
- 25:45this little time bomb sitting
- 25:47here with this, again, well
- 25:49formed necrotic
- 25:50core,
- 25:51which which has outward pressure.
- 25:52There's a lot of hemostatic
- 25:54forces going on here. And,
- 25:55again, metabolically active thin fibers
- 25:57cap ruptures, and then in
- 25:58the mat... In a matter
- 25:59of minutes,
- 26:01you can then get this
- 26:02massive thrombotic occlusion.
- 26:04So, again,
- 26:05patient, you know, it's like
- 26:06a normal EKG. They've got
- 26:08no idea that they've got
- 26:09this type of lesion.
- 26:10Probably
- 26:11two thirds or three quarters
- 26:12of you have coronary disease,
- 26:14and, hopefully,
- 26:15relatively few of you have
- 26:17thin cap fibroatheromas.
- 26:18You just got more of
- 26:19that garden variety, either fibrocalcific
- 26:22or fibrotic,
- 26:24disease.
- 26:24But some will have these
- 26:26tiktvas, and these are the
- 26:27ones that cause the trouble.
- 26:31And we always... In the
- 26:32volatile plaque field, we make
- 26:33the analogy that these are
- 26:35like volcanoes.
- 26:36Because when you look at
- 26:37these from a cross sectional
- 26:38point of view, this is
- 26:39kind of what they look
- 26:40like. You can see the
- 26:41well formed necrotic core with
- 26:42the... You can see the
- 26:43cholesterol clefts.
- 26:45And then you can see
- 26:46right at the tip, there's
- 26:47this very thin fibrous cap,
- 26:48and it's just, you know,
- 26:49waiting to rupture. But you
- 26:51can't tell. Before that, it's
- 26:52a dormant volcano. You have
- 26:54no idea when a volcano
- 26:55is gonna go
- 26:57off. Or maybe we can
- 26:58figure out when it's gonna
- 27:00go off. Maybe we can
- 27:01at least identify
- 27:03the morphology and the biochemistry
- 27:05of that plaque compared to
- 27:07the other plaques that I
- 27:08showed you.
- 27:09And, I'm not gonna spend...
- 27:10I could spend an hour
- 27:11talking about this aspect of
- 27:13it, but with intravascular imaging,
- 27:15starting with grayscale IVUS, then
- 27:17moving to VH IVUS, which
- 27:19is a radio frequency IVUS,
- 27:21where we can color code
- 27:22the different types of plaques,
- 27:24going to optical coherence tomography,
- 27:26and, NIRS infrared spectroscopy, which
- 27:29is a way of looking
- 27:30at the chemistry of the
- 27:31plaque,
- 27:31we can,
- 27:33basically differentiate the five types
- 27:35of plaques
- 27:36by their pictures that we
- 27:38can create. And this is
- 27:39a classification that Renu Vermani,
- 27:41probably the most well known
- 27:42cardiac pathologist, came up with.
- 27:44We can differentiate these plaques
- 27:46from fibrocalcific
- 27:47to fibrous to pathological gable
- 27:49thickening,
- 27:50and then the fibroatheromas.
- 27:51They're the ones that have
- 27:52that well formed necrotic core.
- 27:54And if there's a thick
- 27:56cap, that's a thick cap
- 27:57fibroatheromat.
- 27:58And if there's a thin
- 27:59cap, which is usually less
- 28:00than about sixty five microns,
- 28:02that's a ticfah. And those
- 28:04are the ones that are
- 28:05really the highest risk.
- 28:08So a number of years
- 28:09ago, we came up with
- 28:10an idea to see if
- 28:12we could actually prospectively
- 28:14identify these lesions using intravascular
- 28:16imaging. We know that you
- 28:18couldn't do it by angiography.
- 28:19You couldn't do it by
- 28:20any noninvasive,
- 28:21technique. And, again, most of
- 28:23these lesions are not flow
- 28:25limiting, so they're not hemodynamically
- 28:26obstructive. They look mild on
- 28:28the angiogram.
- 28:29So we did a study,
- 28:31called the prospect study. And
- 28:33I worked with Alexandra on
- 28:34this, and now I'm gonna
- 28:35divert... Digress for a second
- 28:36and tell a story about
- 28:38Alexandra
- 28:39because I said, so here's
- 28:40what I wanna do. I
- 28:41wanna do a study
- 28:42where we're gonna take about
- 28:43a thousand patients or so,
- 28:45and we're gonna do,
- 28:47a three vessel angiograms, and
- 28:49we're gonna do three vessel
- 28:50intravascular imaging. Okay?
- 28:53And Alexander was the director
- 28:54of the angiographic core laboratory
- 28:56at the Cardiovascular Research Foundation,
- 28:57and I said, we wanna
- 28:58get you these films. And
- 28:59I don't want you to
- 29:00look at the lesions. I
- 29:01want you to look at
- 29:02every single millimeter of the
- 29:03coronary tree
- 29:05and do QCA of every
- 29:06single millimeter of the coronary
- 29:08tree. And she said, you
- 29:09know, Greg, that... That's ridiculous.
- 29:11That can't be done. That
- 29:12would take a technician days
- 29:14to do that. And I
- 29:15said, we can do it.
- 29:16I want you to do
- 29:17it. Will you do it?
- 29:18And so she agreed.
- 29:19And then in the intravascular
- 29:21imaging laboratory where we had,
- 29:23the director was Akiko Mahara,
- 29:26we said, Akiko, you have
- 29:27to go through this, you
- 29:28know, every frame by frame,
- 29:30and you have to analyze
- 29:31every single frame of the
- 29:32coronary tree.
- 29:34And then we would, at
- 29:35baseline,
- 29:36prospectively
- 29:37categorize
- 29:38every single bit of atherosclerosis
- 29:41in the main three epicardial
- 29:42coronary arteries, and we'd watch
- 29:43what happened over the next
- 29:44three to four years. So
- 29:45let me show you how
- 29:46this would work.
- 29:48So this is a patient
- 29:49who came in with an
- 29:51occluded proximal LAD. So we
- 29:53took patients with acute coronary
- 29:55syndromes for this study,
- 29:56and the LAD gets treated
- 29:58and, with a successful result
- 30:00than any other high grade
- 30:01lesions. And then we do
- 30:03three vessel imaging
- 30:04of the left main, the
- 30:05LAD, the circumflex in the
- 30:07right coronary artery, the main
- 30:08epicardial branches... Vessels and any
- 30:10major branches.
- 30:12So here, I'm gonna show
- 30:13you is a circumflex.
- 30:15So ignore the occluded LED.
- 30:17That got revascularized. It looked
- 30:18great. And that... The LED
- 30:20did fine. But here's a
- 30:21circumflex.
- 30:22And I'm gonna tell you
- 30:23that this was done, you
- 30:25can see, in February of
- 30:26two thousand and six. And
- 30:27I'm gonna tell you that
- 30:28fifty one weeks later, this
- 30:30patient presented with a non
- 30:32STEMI due to a lesion
- 30:34in this circumflex.
- 30:35And so I'm gonna ask
- 30:36you, which lesion do you
- 30:38think caused it? Do you
- 30:40think your eye immediately gonna
- 30:41go to this forty percent
- 30:43stenosis in the mid in
- 30:44the mid circ? So, you
- 30:46know, who thinks it might
- 30:47have been proximal to that
- 30:49lesion somewhere in the proximal
- 30:50circ
- 30:51that caused a non STEMI
- 30:53within a year?
- 30:55Nobody.
- 30:56Maybe one or two. Who
- 30:57thinks it's gonna be the
- 30:59forty percent stenosis, the focal
- 31:00stenosis in the mid circ?
- 31:03Okay.
- 31:04Okay?
- 31:06Who thinks it's gonna be
- 31:07somewhere
- 31:09after that forty percent stenosis,
- 31:10that little lumpy, bumpy area?
- 31:12Here, we've got three or
- 31:13four. Who thinks it's gonna
- 31:14be one of those two
- 31:15branches, those two distal marginal
- 31:18branches?
- 31:19Hard to know. Well, here's
- 31:20what happened. Okay?
- 31:22So here is now,
- 31:24almost exactly a year later,
- 31:25fifty one weeks later, and
- 31:26you could see there's a
- 31:27new thrombotic,
- 31:29rupture
- 31:30of that lesion. The forty
- 31:31percent stenosis hasn't changed at
- 31:33all. So that was at
- 31:34that site of that arrow
- 31:35at what looks like about
- 31:36an angiographic twenty percent stenosis.
- 31:39So what we had done
- 31:40is we had imaged that
- 31:42whole circumflex and the LAD
- 31:44and the right coronary artery
- 31:45at baseline. So now we
- 31:46go back to baseline, and
- 31:47let's look at the way
- 31:48the atherosclerosis
- 31:50looked like in that circumflex.
- 31:52And here is basically what
- 31:53it looked like.
- 31:54This was a technique called,
- 31:56radiofrequency
- 31:57IVUS where, again, we could
- 31:58color code the different plaques,
- 32:00and the red is the
- 32:01kind of plaque that we
- 32:02worried about. And so we
- 32:03pull back
- 32:04from that asterisk, in this
- 32:06case, all the way up
- 32:07to the left main,
- 32:08and the, imaging actually found
- 32:11three different lesions. And those
- 32:13little,
- 32:14three peaks are three different
- 32:15lesions as the plaque is
- 32:16getting more severe.
- 32:18So if we just focus
- 32:19at site one, which is
- 32:20where the plaque was that
- 32:22caused the problem,
- 32:23each of those frames at
- 32:24the bottom are every about
- 32:26five hundred microns
- 32:28through that, plaque. And the
- 32:30first thing you could see
- 32:31from the gray scale at
- 32:32the bottom is this was
- 32:33a big bulky plaque.
- 32:35Okay? Even though it looks
- 32:36angiographically
- 32:37like a twenty percent stenosis,
- 32:39it was actually seventy six
- 32:40percent
- 32:41of that lumen was full
- 32:42of plaque.
- 32:43And it just shows you
- 32:44the angiogram is a terrible
- 32:46discriminator
- 32:47of how much atherosclerosis
- 32:48there was. So a huge
- 32:49amount of atherosclerosis.
- 32:51So you could see by
- 32:52QCA from Alexander's lab, the
- 32:54reference vessel diameter is two
- 32:55point eight two millimeters. It
- 32:56was a twenty eight point
- 32:57six percent stenosis.
- 32:59It was six point eight
- 33:00millimeter long lesion at that
- 33:01site. But by VHIVUS,
- 33:04it had a seventy six
- 33:05percent plaque burden. The middle
- 33:07luminal area was five point
- 33:08three millimeter squared, which is
- 33:10not usually obstructive,
- 33:11and it was coded as
- 33:12a core lab as a
- 33:13thick capped fibroatheroma.
- 33:16So that was this lesion.
- 33:18So what we did was
- 33:19we did this in about
- 33:21seven hundred patients, and we
- 33:22characterized thirty six hundred lesions
- 33:24in the coronary tree. A
- 33:26lesion had to have at
- 33:27least a forty percent placard.
- 33:29And then we looked to
- 33:30see what kind of lesions
- 33:32were causing future events.
- 33:34And our hypothesis was, based
- 33:36on what Vermani had taught
- 33:37us, is that the tikvas
- 33:38would be the highest risk,
- 33:40then the thick cap fibroatheromas
- 33:42would be the intermediate risk,
- 33:44and all the other lesions
- 33:45would have almost no risk.
- 33:48So the first thing that
- 33:49we learned
- 33:50was that the number one
- 33:51predictor of events was the
- 33:53amount of plaque that was
- 33:54there. And as you could
- 33:55see,
- 33:57if you had greater than
- 33:58seventy percent plaque burden,
- 34:00in a lesion that looked
- 34:01angiographically
- 34:02mild on the right side
- 34:03of the, graph,
- 34:05each of those lesions, and
- 34:06these are lesion specific event
- 34:08rates within a median follow-up
- 34:10of three point two years,
- 34:11had a nine point five
- 34:13percent event rate of causing
- 34:14an acute coronary syndrome, either
- 34:16new unstable angina
- 34:18requiring hospitalization,
- 34:20myocardial infarction,
- 34:21or attributed,
- 34:22cardiac death.
- 34:24If it was a sixty
- 34:24to seventy percent stenosis,
- 34:26those lesions had about a
- 34:27two point five percent event
- 34:29rate. And then you could
- 34:30see if you get below
- 34:31that... In fact, when you
- 34:32get to below forty percent,
- 34:33we didn't even call those
- 34:34lesions.
- 34:35Okay? And there were thousands,
- 34:37probably tens of thousands of
- 34:39those, and not a single
- 34:41site that had less than
- 34:42forty percent plaque caused an
- 34:44event within about three to
- 34:46four year follow-up.
- 34:48So the first thing that
- 34:49came out of prospect was,
- 34:51the me... On the mean
- 34:52baseline diameter stenosis of those
- 34:54lesions by QCA was thirty
- 34:55two percent. So by the
- 34:57angiogram, these things look trivial,
- 34:59and that's why we don't
- 35:00treat them. But these are
- 35:01the ones that are causing,
- 35:03unstable angina heart attacks and
- 35:05cardiac death.
- 35:07So the first thing that
- 35:07we did was explode
- 35:09a major myth that was
- 35:11prevalent in cardiology at that
- 35:12time.
- 35:13And that was that vulnerable
- 35:15plaques, the ones that place
- 35:16the patients at risk, are
- 35:18not mild. They're actually very
- 35:20severe, but they just look
- 35:21mild angiographically.
- 35:23So you have to stop
- 35:24relying on the angiogram.
- 35:26And as an interventional cardiologist,
- 35:28I'm in love with the
- 35:29angiogram,
- 35:29but for this purpose, it
- 35:31doesn't tell us what we
- 35:32need to know.
- 35:35However,
- 35:36plaque is not enough.
- 35:37Okay? Because there's stable plaque,
- 35:40like that pathological interval thickening
- 35:42that I showed you early
- 35:43on, and then there is
- 35:44the kind of vulnerable plaque.
- 35:46And
- 35:47I was as surprised as
- 35:49anybody
- 35:50to see that the hypothesis
- 35:51worked out. And this paper
- 35:53was published in the New
- 35:54England Journal and, was kind
- 35:56of revolutionary in its time.
- 35:58But you could see here
- 35:59that if we had a
- 36:00large plaque burden with a
- 36:02thin cap fibroatheroma
- 36:04as prospectively identified,
- 36:06it had a sixteen percent
- 36:07likelihood that one lesion
- 36:09of causing a major event
- 36:10within three years.
- 36:12If it was a thick
- 36:12cap fibroatheroma,
- 36:14it had an intermediate risk,
- 36:16eight point seven percent. And
- 36:17if it was any of
- 36:18the other types that we
- 36:19thought were gonna be stable,
- 36:21they were really stable. And
- 36:22in fact, even though there
- 36:23was a lot of plaque,
- 36:24it conferred no extra risk
- 36:26whatsoever. Again, it might have
- 36:27caused angina,
- 36:28but it didn't cause any
- 36:30risk of a cardiovascular death
- 36:31or myocardial infarction.
- 36:34We then went on and
- 36:35we did subsequently a study
- 36:37called prospect two,
- 36:38which was a similar type
- 36:39of prospective natural history multimodality
- 36:42imaging study, very similar. But
- 36:44instead of using radio frequency
- 36:46IVS, we used near infrared
- 36:47spectroscopy
- 36:48and IVUS. And near infrared
- 36:50spectroscopy
- 36:51is when it was approved
- 36:52by the FDA,
- 36:53was,
- 36:54touted as the most accurate
- 36:56spectroscopic
- 36:57technique to identify any tissue
- 36:59type in the body. And,
- 37:00basically, it's very simple. It
- 37:02basically looks up and down
- 37:03the artery, and yellow is
- 37:05lipid, okay, cholesterol
- 37:07and cholesterol esters, and red
- 37:09is not. And the wavy
- 37:10black thing is wire artifact.
- 37:12And so here is a
- 37:14example from prospect two,
- 37:16where you can see this
- 37:17was a right coronary artery.
- 37:18There was... It was intervened
- 37:20on where it says culprit
- 37:21stent in the distal right,
- 37:22and then we imaged the
- 37:23entire right coronary artery.
- 37:25Here, we did fractional flow
- 37:27reserve in this study to
- 37:28prove that all of these
- 37:29were physiologically non significant lesions.
- 37:31The FFR was normal, point
- 37:32nine four.
- 37:33And here you can see
- 37:35I point to the arrow
- 37:37where what happened here,
- 37:39at,
- 37:40about three years later is
- 37:42that that lesion, which was
- 37:43about twenty percent at baseline,
- 37:45suddenly became ninety five percent
- 37:47and caused a,
- 37:49a non sigma elevation myocardial
- 37:51infarction. And then if you
- 37:52go back to the baseline,
- 37:53what you can see
- 37:55is up and down, if
- 37:56you look at the red
- 37:57carpet, up and down that
- 37:58vessel, this is the whole
- 38:00vessel splayed out longitudinally.
- 38:02There's almost no lipid in
- 38:04the vessel exactly at where
- 38:05that big arrow is.
- 38:07And if you notice the
- 38:08rest of the vessel, nothing
- 38:10happens to the rest of
- 38:10the vessel three years later.
- 38:12But that area is the
- 38:14place that ruptures and then
- 38:15thrombosis.
- 38:16And then when you look
- 38:17at it and you superimpose
- 38:18the IVUS at baseline,
- 38:20you can see that the
- 38:21plaque burden was eighty percent
- 38:22at that lesion.
- 38:24So huge positive remodeled vessel
- 38:26with a lot of plaque,
- 38:27which was very, very lepidic,
- 38:30and, that's a vulnerable plaque.
- 38:33So in this study, we
- 38:34coined the term a two
- 38:36feature vulnerable plaque, which is
- 38:38one, a lot of plaque
- 38:39burden, greater than seventy percent
- 38:40stenotic,
- 38:41and in this case, with
- 38:43high lipid content.
- 38:45And when you have both
- 38:46of those features present, you
- 38:47need both, and then you've
- 38:49got a high risk plaque.
- 38:53Finally,
- 38:53others people, not us, but
- 38:55other people did studies with
- 38:56optical coherence tomography, and this
- 38:58is the only technique. It's
- 38:59it's like intravascular ultrasound,
- 39:01but using laser light, so
- 39:03it's got a much higher
- 39:04resolution of ten to twenty
- 39:05microns. And it's the only
- 39:06technique where you can really
- 39:08see the thickness of the
- 39:09fibrous cap. The only one
- 39:10where you can really say
- 39:11is it less than or
- 39:12greater than sixty five microns.
- 39:14And sure enough, when they
- 39:15define a thin cap fibroatheroma
- 39:18with a thin fibrous cap
- 39:19and a large lipid arc,
- 39:21then you distinguish which lesions,
- 39:23in this case, the study
- 39:25combined,
- 39:26trial
- 39:27showed which lesions were the
- 39:29high risk lesions.
- 39:31So all of this gets
- 39:33put into multivariable analysis to
- 39:35see if it really, hangs
- 39:36out, And it turns out
- 39:37none of the clinical features
- 39:39predict this, none of the
- 39:40angiographic features predict this, but
- 39:42intravascular imaging predicts it. And
- 39:44you can see the three
- 39:45largest studies, PROSPECT one, PROSPECT
- 39:47two, and then, JANG, which
- 39:49was a large OCT study.
- 39:51And you can see what
- 39:51the big predictors are. Are.
- 39:53It's plaque burden greater than
- 39:54seventy percent.
- 39:55It is a thin cap
- 39:57fibroethronoma
- 39:58by either,
- 39:59virtual histology
- 40:01or by OCT.
- 40:02And then it is,
- 40:04a large lipid content by
- 40:06near infrared spectroscopy.
- 40:08Minimal luminal area being small
- 40:10has been kind of a
- 40:11borderline predictor, but it's probably
- 40:13not as important as the
- 40:15others.
- 40:17So can we identify vulnerable
- 40:18plaque? We have answered that
- 40:20question definitively.
- 40:22The answer is yes. There
- 40:23have now been nine
- 40:25prospective
- 40:25studies like this that, based
- 40:27on, what Alexandra and I
- 40:29did in Prospect one, and
- 40:30that's now become the standard
- 40:32methodology to do it,
- 40:34that have shown that radio
- 40:35frequency IVUS, NEARS IVUS, OCT,
- 40:38and, yes, probably
- 40:39noninvasively
- 40:40with CTA, that could be
- 40:41a whole another lecture, can
- 40:43identify non full limiting plaques
- 40:45that place patients at risk
- 40:46for future events.
- 40:48Okay.
- 40:49So you've gotta see beyond
- 40:51the angiogram. You gotta take
- 40:52that NHLBI
- 40:53dynamic lesion, which you can't
- 40:55tell. Is it a stable
- 40:56atherosclerotic
- 40:57plaque,
- 40:58inactive, noninflamed,
- 41:00or is it a vulnerable
- 41:03atherosclerotic
- 41:03plaque, which is active and
- 41:05inflamed and has this thin
- 41:06fibers cap and necrotic core?
- 41:08And now we do have
- 41:09imaging techniques that can clearly
- 41:11differentiate those if we go
- 41:13to the trouble of doing
- 41:14it. So why would we
- 41:15wanna go to the trouble
- 41:16of doing it? It will
- 41:17be nice to tell people
- 41:18their prognosis,
- 41:19but, obviously, we'd like to
- 41:21affect it.
- 41:22So what do we do
- 41:23about this? Okay? Here's a
- 41:25sixty eight year old diabetic
- 41:26woman with atypical angina who
- 41:29was treated with aspirin and
- 41:30atorvastatin,
- 41:31and because she had atypical
- 41:32angina, she ended up getting
- 41:34cathed, and she had whistle
- 41:35clean coronaries
- 41:36except for this mid LAD
- 41:38lesion, maybe a twenty, twenty
- 41:40five percent stenosis.
- 41:42So she had atypical angina,
- 41:44so let's do a fractional
- 41:45flow reserve. And her fractional
- 41:47flow reserve is point eight
- 41:48eight normal. Right? Above point
- 41:50eight zero is normal.
- 41:51So... Okay.
- 41:53Mild stenosis,
- 41:55nonobstructive
- 41:56disease, probably not angina.
- 41:58So we'll just go ahead
- 41:59and treat her. And what
- 42:01happens?
- 42:02Three months later, she thrombosis,
- 42:04that thirty percent stenosis. And
- 42:06at that time, the doc
- 42:07cited, oh, what's going on
- 42:09here? I'm gonna image it.
- 42:10And now he image it.
- 42:11He first aspirates the thrombus,
- 42:12and then he images it.
- 42:13And here he sees... This
- 42:15is the OCT image showing
- 42:16three hundred and sixty degrees
- 42:18of lipid, a thin ruptured
- 42:19fibrous cap.
- 42:21So if that was detected
- 42:23at that thirty percent
- 42:24point, maybe we could have
- 42:26put that patient on a
- 42:27PCSK nine inhibitor. Maybe we
- 42:29could have drove her LDL
- 42:30down to twenty. Maybe we
- 42:31could have done PCI. Maybe
- 42:33she should have gotten a
- 42:33LIMA. Could something have prevented
- 42:35that that we're not doing
- 42:36today?
- 42:38Here's another case. Here's a,
- 42:40patient who presented with unstable
- 42:42angina, a fifty seven year
- 42:43old woman. She had a,
- 42:44you know, subtotal stenosis,
- 42:47in the mid right coronary
- 42:48artery. Then there's another thirty
- 42:51percent stenosis. So should that
- 42:52be treated or not? Well,
- 42:54in this case, the doc
- 42:55actually did,
- 42:57intravascular ultrasound with near infrared
- 42:59spectroscopy,
- 43:00and here's what they found.
- 43:02They found that both of
- 43:04those lesions, the culprit lesion,
- 43:05which is the blue arrow,
- 43:06and that thirty percent stenosis
- 43:09was a lipid rich plaque.
- 43:11So he actually said, well,
- 43:12look. I'm gonna stent that
- 43:13mid lesion anyway, so why
- 43:14don't I just use a
- 43:15longer stent and let me
- 43:17cover that, a vulnerable plaque
- 43:19more distally? That's not exactly
- 43:21in the guidelines, but I
- 43:22think it's reasonable to do
- 43:24rather than ending a stent
- 43:25very close to it. So
- 43:26he did that,
- 43:28and,
- 43:29you know, here's what he
- 43:30got. It looks like a
- 43:32beautiful result, and you could
- 43:33see the near infrared spectroscopy
- 43:35after the stent. There's a
- 43:36little bit of lipid left,
- 43:37but not much. We often
- 43:38actually embolize a lot of
- 43:40lipid during these procedures.
- 43:42But what he didn't notice
- 43:43or didn't pay attention to
- 43:45was this other lesion that
- 43:46I got a bracket around
- 43:47at the distal right coronary
- 43:48artery. And it was about
- 43:50a twenty, thirty percent stenosis,
- 43:52but he didn't image down
- 43:53that far. And he just
- 43:54left that alone. But I'm
- 43:56sorry. He didn't image down
- 43:57that far initially, but he
- 43:58did image down that far
- 44:00on the second procedure. And
- 44:01here you could see the
- 44:02square to the right at
- 44:03the bottom, and that is
- 44:04an intensely lepidic plaque,
- 44:07but he didn't wanna get
- 44:08into that. We don't have
- 44:09any indication today to treat
- 44:10these non flow limiting vulnerable
- 44:12plaques, so he left it
- 44:13alone. And so five years
- 44:15later,
- 44:16the patient comes in with
- 44:17an inferior STEMI
- 44:19due to a rupture of
- 44:20that plaque.
- 44:22So this happens again and
- 44:23again and again.
- 44:26So can we improve the
- 44:27outcomes of what we're doing?
- 44:28I'll tell you why I
- 44:29really do believe
- 44:30we can.
- 44:32You take a trial like
- 44:33the complete trial,
- 44:34and many of you remember
- 44:36this. This was four thousand
- 44:37STEMI patients with multivessel disease,
- 44:40where you treat the infarct
- 44:41artery, of course, and then
- 44:43they randomized patients to treat
- 44:45all the other seventy percent
- 44:46stenoses,
- 44:47just prophylactically
- 44:48versus leaving them alone and
- 44:50treating them medically. And this
- 44:51was a markedly positive trial.
- 44:53It showed a reduction in
- 44:54cardiovascular death and new myocardial
- 44:56infarction, particularly
- 44:57reducing MI, unstable angina, and
- 45:00and unplanned revascularization.
- 45:02And because of this and
- 45:03other smaller trials, this is
- 45:05now class one a in
- 45:06the guidelines. This is how
- 45:07we treat patients with STEMI
- 45:09and multivessel disease. We do
- 45:10complete revascularization
- 45:12of angiographically
- 45:13guided seventy percent or more
- 45:15stenosis.
- 45:16So can we do better?
- 45:18And I'm telling you, I
- 45:19think we can do better.
- 45:20And why is that? Well,
- 45:21they did an OCT substudy
- 45:23where they actually used OCT
- 45:25of all three vessels,
- 45:27within this study, and they
- 45:28actually found that two thirds
- 45:30of the patients
- 45:31had thin cap fibroatheromas.
- 45:34And, the lesions that were
- 45:36obstructive, those seventy percent untreated
- 45:38lesions, that was about thirty
- 45:40five percent per lesion,
- 45:42was a thin cap fibroatheroma.
- 45:44But all of the non
- 45:45obstructive lesions,
- 45:46that... They were often thin
- 45:48cat fibroatheromas
- 45:49as well. So, overall, fifty
- 45:51six percent
- 45:52of these untreated lesions that
- 45:55got randomized,
- 45:56the ones that were nonobstructive,
- 45:58more of those were thin
- 45:59cat fibroatheromas
- 46:01than the ones they treated.
- 46:02And if you looked at
- 46:03the characteristics
- 46:04of the lesions that got
- 46:05treated and didn't get treated,
- 46:06they look exactly the same
- 46:07by intravascular imaging.
- 46:09So I think, actually, they
- 46:10probably could have more than
- 46:11doubled the treatment effect size
- 46:13if they had treated all
- 46:14the other lesions, but they,
- 46:16of course, were seduced by
- 46:17the angiogram. They said that
- 46:18the seventy percent stenosis, those
- 46:19are the ones we should
- 46:20pay attention to. But, actually,
- 46:22the reason the trial
- 46:23succeeded
- 46:24was, in my opinion, is
- 46:26that they treated the thin
- 46:27cap fibroatheromas
- 46:29within those seventy percent stenosis.
- 46:32So
- 46:33no one else short of
- 46:35Eugene Braunwald,
- 46:37two decades ago
- 46:39thought that we need to
- 46:40think out of the box.
- 46:41Okay? We need to do
- 46:43vulnerable plaque and vulnerable patient
- 46:45screening and treatment.
- 46:46And he said that, basically,
- 46:47we should start with the
- 46:48framing and risk score to
- 46:49risk stratify patients.
- 46:51And the patients that have
- 46:52somewhat increased risk, of course,
- 46:54should have risk factor modification.
- 46:56But then those that were
- 46:57the high... Highest risk should
- 46:59have some sort of noninvasive
- 47:00assessment for vulnerable plaques.
- 47:03And that if you detect
- 47:04vulnerable plaques by noninvasive
- 47:06assessment,
- 47:06that you should then have
- 47:08an invasive test for vulnerable
- 47:09plaques. And then if you
- 47:11find vulnerable plaques, you should
- 47:13do some sort of new
- 47:14treatment. He didn't know what
- 47:15the new treatment was back
- 47:16then.
- 47:17So I would say that
- 47:18we have these. We we
- 47:20we can further risk stratify
- 47:21patients beyond our
- 47:23our classic risk factors
- 47:25by looking for underlying inflammation.
- 47:27Simple tests such as the
- 47:29HSCRP,
- 47:30which again reflects...
- 47:32Is very related to the
- 47:33progression of atherosclerosis
- 47:34and the destabilization
- 47:36of plaques.
- 47:37And then that can lead
- 47:38us to do noninvasive
- 47:39testing,
- 47:40such as CTA. And CTA,
- 47:42especially with photon counting CTA,
- 47:44is really emerging as the
- 47:45noninvasive
- 47:46test for this type of
- 47:47screening.
- 47:48Then we can go to
- 47:49the lab, and, yes, we
- 47:51have NIRS IVUS, and we
- 47:52have OCT. We can now
- 47:53confirm,
- 47:55you know, beyond certainty what
- 47:56vulnerable plaques are, and we
- 47:58actually do have new treatments
- 48:00per... We have pharmacologic intensification,
- 48:02and we have stents and
- 48:04scaffolds.
- 48:06So
- 48:07we have four randomized trials
- 48:09looking at pharmacologic therapy, either
- 48:11high dose statins or PCSK
- 48:13nine inhibitors
- 48:14in patients specifically with vulnerable
- 48:16plaques. And these were mechanistic
- 48:18studies. They were imaging studies
- 48:20where they did find specifically
- 48:22vulnerable plaques,
- 48:23and then they randomized patients
- 48:25to either placebo or hydostat
- 48:26or PCSK nine inhibitors. And
- 48:28all four trials were positive.
- 48:30They showed that what you
- 48:31would do is you would
- 48:33delipidate the plaque with intensive,
- 48:35LDL lowering therapy.
- 48:36You would thicken the fibrous
- 48:38cap, and you would slightly
- 48:39decrease plaque burden, but only
- 48:41one to two percent. The
- 48:43main effects are not on
- 48:44plaque burden. It's on the,
- 48:46compositional
- 48:47structure of the plaque.
- 48:49So how big an effect
- 48:50does this have?
- 48:51Well, if you're not targeting
- 48:53patients with vulnerable plaque and
- 48:55you wanna treat everybody, which
- 48:56is what big pharma always
- 48:57wants to do, you do
- 48:59have a positive effect, but
- 49:00it's a minimal effect. So
- 49:02if you look at the
- 49:03Fourier and the ODSI outcomes,
- 49:05outcome trials in twenty to
- 49:07thirty thousand randomized patients, these
- 49:09are the PCSK nine inhibitor
- 49:11trials, they're both positive.
- 49:13But look at one, how
- 49:14much they're positive.
- 49:15They reduce major adverse cardiac
- 49:17events by about two percent
- 49:20in a four year period.
- 49:21So it's about point five
- 49:23percent per year, and you
- 49:24can see there's still a
- 49:25high residual risk at the
- 49:27end of the day. So
- 49:28they are having some effect,
- 49:30but you're treating a lot
- 49:31of patients who probably don't
- 49:33need to be treated, and
- 49:34you are having some effect
- 49:35on the ones that do
- 49:36need to be treated, but
- 49:37it's a small overall global
- 49:40effect.
- 49:42So we and others had
- 49:43come up with the idea
- 49:44that perhaps
- 49:45we're treating the wrong lesions
- 49:46with stents and with bypass
- 49:48surgery, but this is probably
- 49:49most relevant to stents. And
- 49:50if we could identify vulnerable
- 49:52plaques, like you've got here
- 49:54an LAD. This was from
- 49:56two. Here's a ten percent
- 49:57osteoLED
- 49:58stenosis.
- 49:59Nobody in their right mind
- 50:00today would think about treating
- 50:01this. But when you image
- 50:03this with IVUS and, near
- 50:05infrared spectroscopy,
- 50:06you see a seventy five
- 50:07percent bulky plaque with a
- 50:10very high lipid content, a
- 50:12sixty percent lipid.
- 50:13This is a, quote, widow
- 50:14maker lesion. And this is
- 50:16just as high risk a
- 50:17plaque as if it looked
- 50:18like this, but it was
- 50:19an eighty percent stenosis.
- 50:21So you... What you could
- 50:23do is you could either
- 50:24leave that alone and take
- 50:25a chance that it might
- 50:26rupture in thrombose,
- 50:28or perhaps you'd put a
- 50:29stent on it. And a
- 50:30stent in a scaffold
- 50:32always invokes an obligate amount
- 50:34of healing response, which is
- 50:35what's called neointimal hyperplasia or
- 50:38scar tissue. And our concept
- 50:39and others' concepts were that
- 50:41the scar tissue would thicken
- 50:43the cap. So you now
- 50:44make a thick fibrous cap.
- 50:46And, also, by dilating, you
- 50:47also help dilipidate the plaque.
- 50:50So this was proven pathologically
- 50:52by Pedro Marino and others.
- 50:54They, you know, fed,
- 50:56rabbits, hypercholesterolemic
- 50:58diet, and they could create,
- 50:59these foam cell laden lesions
- 51:01that look like thin cap
- 51:02fibroatheromas.
- 51:04And they would stent them,
- 51:05and they would then,
- 51:06find out that this is
- 51:07what it would look like.
- 51:08And you could see here
- 51:09basically the, oblong stent strut.
- 51:12And below in blue, you
- 51:13could see the old fibrous
- 51:15cap, and then you could
- 51:16see the neointema on top,
- 51:18which is the new fibrous
- 51:19cap. So you took what
- 51:20was a sixty micron,
- 51:22fibrous cap, and now you
- 51:23turn it into a two
- 51:24hundred and fifty micron fibrous
- 51:25cap.
- 51:27So we ran the first
- 51:28pilot study called Prospect Absorb
- 51:30to see if this would
- 51:31be safe. Could it could...
- 51:32Could you even do this,
- 51:33and would it mechanistically work?
- 51:35And what we did was
- 51:36we randomized a hundred and
- 51:37eighty two patients,
- 51:39that had a large plaque
- 51:41burden and non flow limiting
- 51:42lesions to either get a
- 51:44bioresorbable
- 51:45scaffold called the absorb scaffold
- 51:47versus medical therapy alone, and
- 51:49we followed the patients for
- 51:51four years.
- 51:52And we brought them all
- 51:53back to reimage them at
- 51:55twenty five months to see
- 51:56if, mechanistically,
- 51:58it would happen what we
- 51:59thought would happen.
- 52:00And sure enough, we made
- 52:02the lumen much larger.
- 52:03You could see the treated
- 52:05group went from three point
- 52:06two to six point nine
- 52:07millimeters squared, whereas the untreated
- 52:09group stayed the same, or
- 52:11got slightly smaller.
- 52:12We created a NeoCap that
- 52:14was two hundred and ten
- 52:15microns thick, and we delipidated
- 52:17the plaque. We went from
- 52:18thirty three percent lipid down
- 52:20to about six percent lipid
- 52:21at twenty five months.
- 52:23Now this trial at a
- 52:24hundred and eighty two patients
- 52:25was not powered for clinical
- 52:26events, but, nonetheless,
- 52:28if you look at what
- 52:29happened with the lesions that
- 52:30got treated,
- 52:31there was about over four
- 52:33years. The ones that were
- 52:34randomized to use medical therapy
- 52:35had an eleven percent lesion
- 52:37specific event rate versus four
- 52:39percent in the ones that
- 52:40got a scaffold.
- 52:42So pictures are always worth
- 52:43a thousand words.
- 52:45So here was a patient
- 52:46that had two lesions.
- 52:48So here you can see
- 52:50a circumflex marginal lesion in
- 52:52the first, angiogram,
- 52:53and in the second angiogram,
- 52:55you could see a mid
- 52:55right coronary lesion. And both
- 52:57of these had... Were negative
- 52:58by FFR or point nine
- 53:00zero, so no indication to
- 53:01treat today.
- 53:02They were both
- 53:04very bulky lipidic plaques.
- 53:06So when there were two
- 53:07plaques, we would tell the
- 53:08operator, randomize the lesion that
- 53:11looked like it supplied the
- 53:12most amount of myocardium.
- 53:13So in this case, they
- 53:14randomized the right coronary lesion,
- 53:16and this patient got randomized
- 53:18to, a biorasorbital
- 53:20scaffold.
- 53:21And so here it was
- 53:22before, and here it was
- 53:23after the scaffold. And you
- 53:25could see the lumen is
- 53:26larger. We dilipidated the plaque.
- 53:28You see the yellow rim
- 53:29that shows you where the
- 53:30lipid is, and there was
- 53:31lipid at baseline. There's no
- 53:33lipid afterwards.
- 53:35So the patient did really
- 53:36well for about nine months
- 53:38and then came back with
- 53:40progressive angina, and so the
- 53:41patient got recapped at nine
- 53:43months. And the right coronary
- 53:45looked beautiful.
- 53:46Okay? But the circumflex... And
- 53:47this is the one that
- 53:48was not treated. Here's what
- 53:50happened. This was again a
- 53:51vulnerable plaque, and the circumflex
- 53:54occluded
- 53:55in that nine month period.
- 53:57So the operator said, well,
- 53:58this is a moderate sized
- 54:00vessel. I don't think I'd
- 54:01have a very good chance
- 54:02of opening it up. Let
- 54:03me just leave this alone,
- 54:04and we'll treat the patient
- 54:05with more anti anginal drugs
- 54:06because it's now very, very
- 54:07stable.
- 54:08And that's what it did.
- 54:09The patient ended up with
- 54:10mild angina, but was stable.
- 54:12And then the patient came
- 54:13back at twenty five months.
- 54:15The circumflex looked the same,
- 54:16and here's what the right
- 54:17corner looked like. So you
- 54:19got baseline, immediate after, in
- 54:20the middle, and then at
- 54:22twenty five months. And now
- 54:23you can see we've, quote,
- 54:24stabilized
- 54:25this vulnerable plaque.
- 54:27But what we clearly needed
- 54:28was an outcomes trial,
- 54:30and, we couldn't get one
- 54:31funded in the United States.
- 54:33So, fortunately, in South Korea,
- 54:36they had funding to be
- 54:37able to do this. So
- 54:38I worked with a leading
- 54:40South Korean group, SJ Park,
- 54:41who's published a lot of
- 54:42papers in the journal,
- 54:44and we designed the PREVENT
- 54:45trial. And this was sixteen
- 54:47hundred patients
- 54:48with a flow,
- 54:50a negative flow... A non
- 54:51flow limiting vulnerable plaque,
- 54:54mostly chronic coronary syndromes that
- 54:56had no other reason to
- 54:57treat except they had a
- 54:58vulnerable plaque. And we used
- 55:00a variety of different imaging
- 55:01techniques that could be used,
- 55:02and they got randomized one
- 55:04to one to either, bioresorbable
- 55:06scaffold or metallic drug eluting
- 55:08stent versus medical therapy alone.
- 55:10And this was a powered
- 55:11randomized trial to reduce target
- 55:13vessel failure at two years.
- 55:15And as we published in
- 55:16The Lancet,
- 55:18yes, target vessel failure, the
- 55:20the vessel that had that
- 55:21vulnerable plaque, three point four
- 55:23percent of them within two
- 55:24years had major adverse events
- 55:26compared to point four percent
- 55:28that had preventive
- 55:30PCI treatment. So almost a
- 55:32ninety percent reduction.
- 55:33Almost almost too good to
- 55:35be true.
- 55:36When you look at the
- 55:37kind of events that were
- 55:38prevented,
- 55:38a lot of it was
- 55:39unstable angina and unplanned repeat
- 55:41revascularization,
- 55:42but there was a reduction
- 55:43in death or target vessel
- 55:45MI as well. So everything
- 55:46went in the right direction.
- 55:49The patients were followed up
- 55:51for seven years total, and
- 55:53that initial benefit,
- 55:55lasted throughout the seven year
- 55:56follow-up.
- 55:59And the trial could have
- 56:00been even more positive, and
- 56:01this is a manuscript which
- 56:02is in press, which will
- 56:03be published in about one
- 56:04week because
- 56:06they relied very heavily on
- 56:08grayscale IVUS in that trial.
- 56:10But grayscale IVUS mainly shows
- 56:12you just the plaque. It
- 56:13doesn't tell you the type
- 56:14of plaque.
- 56:15And there were a number
- 56:17of patients that had grayscale
- 56:19IVUS with near spectroscopy.
- 56:21And when we looked at
- 56:22the ones that had a
- 56:23lot of plaque
- 56:24and a lot of lipid,
- 56:25that's the ones on the
- 56:26left, now you see a
- 56:27very high event rate and
- 56:29a marked effect of preventive
- 56:31PCI.
- 56:32In contrast, if you look
- 56:33at the graph on the
- 56:34right, those were the bulky
- 56:36plaques that had very little
- 56:37lipid in them. And those
- 56:39plaques really do great even
- 56:40though they have very little
- 56:41lipid. They're they're not obstructive.
- 56:43A lot of atherosclerosis,
- 56:45but these are not vulnerable
- 56:46plaques. Leave them alone. You
- 56:48don't benefit them, and very
- 56:50little happens to them. So,
- 56:51again, if we were more
- 56:52restrictive at which lesions were
- 56:54enrolled, this could have been
- 56:55much more positive.
- 56:57So
- 56:59there are a lot of
- 57:00other trials that are going
- 57:01on to look at preventative
- 57:03PCI in vulnerable plaque. The
- 57:05first two, as I showed
- 57:05you here, Prospect, Absorb, and
- 57:07Prevent, have been done and
- 57:08were both positive for their
- 57:09endpoints.
- 57:11There's, three others, vulnerable, combined,
- 57:13intervene, and interclima, which have
- 57:14completed enrollment and will report
- 57:16out within the next one
- 57:17to two and a half
- 57:18years depending on follow-up.
- 57:20And we're doing a trial
- 57:22in China called FABR five
- 57:23AMI, which is the largest
- 57:25of all of these, at
- 57:26three thousand patients,
- 57:28looking at a novel vulnerable
- 57:29plaque detection methodology.
- 57:31So there's gonna be a
- 57:32lot more data to come.
- 57:34There's also one trial, which
- 57:35has started recently in China,
- 57:37that I helped them design
- 57:39called the RESTORE trial,
- 57:40and this is actually using
- 57:41a drug coated balloon.
- 57:43So everyone likes this concept
- 57:44of leaving nothing behind if
- 57:46you're gonna treat these nonflow
- 57:47limiting plaques just to change
- 57:49the morphology of the,
- 57:51of the... Of this lesion
- 57:52without,
- 57:54again, putting in a permanent
- 57:55implant. So here, we're trying
- 57:56it with a drug coated
- 57:57balloon in a sixteen hundred
- 57:59patient randomized... Eighteen hundred and
- 58:01sixty patient randomized outcomes trial.
- 58:04So this is my last
- 58:05slide, and now I'll see
- 58:07if you've been paying attention.
- 58:09So should we look for
- 58:10and should we revascularize
- 58:11vulnerable plaques? So this is
- 58:13a real patient. This was
- 58:14a sixty five year old
- 58:15man with exertional dyspnea, was
- 58:17a prior smoker,
- 58:18had hypertension, hypercholesterolemia.
- 58:20His LDL was sixty eight
- 58:21milligrams for desalita on atorvastatin.
- 58:24He had a stress echo,
- 58:26and he had a millimeter
- 58:27of exertional ST segment depression,
- 58:29but normal resting and normal
- 58:31stress LVEF.
- 58:33Okay. So let me ask
- 58:34you the first question. How
- 58:35many people here would do
- 58:37an angiogram
- 58:38versus treat conservatively?
- 58:40So who would do an
- 58:41angiogram
- 58:43with this? I'll let you
- 58:44read it for a second.
- 58:47Lot of risk factors,
- 58:49exertional dyspnea, no angina, but
- 58:51exertional dyspnea,
- 58:52and a little bit of
- 58:53an EKG response on stress
- 58:55echo, but normal stress and
- 58:57rest LV function.
- 59:00Angiogram, anybody?
- 59:02Angiogram.
- 59:04Okay. Interventional cardiologist said, yeah.
- 59:06Yeah. Yeah. Yeah. Alexander said
- 59:08a CT angiogram.
- 59:09Well, it turns out that
- 59:10this patient was the CEO
- 59:13of a Fortune five hundred
- 59:14company.
- 59:15Okay? So, of course, this
- 59:16patient got capped.
- 59:17Okay? That's okay.
- 59:20And here's what the cat
- 59:21showed.
- 59:22And this patient had, again,
- 59:24whistle clean coronary arteries except
- 59:26for these two lesions
- 59:28in the proximal and the
- 59:29mid LAD.
- 59:31Okay?
- 59:32So they're both maybe twenty
- 59:33percent, maybe thirty percent lesions.
- 59:35Okay?
- 59:38So what do you wanna
- 59:40do now? Do you wanna...
- 59:41Do you want to assess
- 59:42those? Do you wanna do
- 59:43a physiologic test to see
- 59:45if they're flow limiting?
- 59:47Maybe that's... You know, that
- 59:48would tell you... That would
- 59:49correlate with his exertional dyspnea.
- 59:51Right? So that's the first
- 59:52thing the doc said to
- 59:53do, and so he did
- 59:54a fractional flow reserve, and
- 59:56it was point eight eight.
- 59:58So those two lesions, even
- 59:59in in concert, are not
- 01:00:01flow limiting. So his exertional
- 01:00:03dyspnea is probably not related
- 01:00:05to any of this.
- 01:00:07Okay? So now do you
- 01:00:08wanna stop?
- 01:00:09Well, again, this was a
- 01:00:11CEO of a Fortune five
- 01:00:13hundred company. So this operator
- 01:00:15said, who who is at
- 01:00:16a very famous institution, by
- 01:00:18the way, said, I'm gonna
- 01:00:19go ahead and I'm gonna
- 01:00:20do,
- 01:00:21a nearest IVUS.
- 01:00:23And here are those two
- 01:00:24lesions.
- 01:00:25Okay? So both of those
- 01:00:27lesions are what we would
- 01:00:28call vulnerable plaques. The first
- 01:00:30lesion's got a plaque burden
- 01:00:31of seventy one percent, and
- 01:00:33it's fifty seven percent lipid.
- 01:00:35Thirty two percent lipid is
- 01:00:36about our cutoff of where
- 01:00:37we get really nervous.
- 01:00:40So sixty percent lipid. The
- 01:00:41second lesion is seventy four
- 01:00:43percent plaque burden and thirty
- 01:00:45six percent lipid. So both
- 01:00:47of those are vulnerable plaques.
- 01:00:49Okay? So now what do
- 01:00:51you do?
- 01:00:52Should PCI
- 01:00:53Do you tell the patient
- 01:00:54about this? We know the
- 01:00:56patient's at higher risk.
- 01:00:57Okay? Should you put the
- 01:00:59patient on a PCSK nine
- 01:01:00inhibitor, get his LDL down
- 01:01:01to twenty? Should that be?
- 01:01:03Okay. All you do. What
- 01:01:05if you talk to the
- 01:01:05patient and he's one of
- 01:01:07these, you know, aggressive guys,
- 01:01:08and he goes, doc, I
- 01:01:09want you to do everything.
- 01:01:10I realize it's not
- 01:01:12indicated by any guidelines anywhere.
- 01:01:15Well, I think, yes, you'd
- 01:01:16probably today put the patient
- 01:01:17on a PCSK nine inhibitor.
- 01:01:19I don't think you'd do
- 01:01:20PCI today, but I'm hoping
- 01:01:22potentially tomorrow after we get
- 01:01:24more data from these randomized
- 01:01:25trials. Thanks very much.
- 01:01:44Maybe I'll start and get,
- 01:01:45and Alexander's can go next.
- 01:01:47So are there any
- 01:01:49elements of people's presentation? And
- 01:01:52I'm... And you know I'm
- 01:01:52gonna ask you about Yeah.
- 01:01:54LV dysfunction
- 01:01:55Yeah. Or heart failure symptoms
- 01:01:57that would
- 01:01:58take taking this patient based
- 01:01:59on what she taught us
- 01:02:00about bromo pry that would
- 01:02:02push you
- 01:02:03to a different answer to
- 01:02:05to... For today? Yeah. Well,
- 01:02:07you know, the the main
- 01:02:08two clinical...
- 01:02:09Sure.
- 01:02:10Well, the main two clinical
- 01:02:11risk factors
- 01:02:13for having thin cat fibroatheromas
- 01:02:16are one, having had either
- 01:02:18an acute or prior acute
- 01:02:19coronary syndromes. So patients who
- 01:02:21have had a prior myocardial
- 01:02:22infarction or unstable angina, again,
- 01:02:24which are not... They're not
- 01:02:26always called by thin cat
- 01:02:27fibroarthromas, by the way. That's
- 01:02:28probably seventy five percent of
- 01:02:29the time I didn't get
- 01:02:30in... Don't have time to
- 01:02:31get into erosion plaques and
- 01:02:32calcific nodules and things. But
- 01:02:35if you had one thin
- 01:02:36cat fibroarthroma
- 01:02:37presentation,
- 01:02:38you're more likely to have
- 01:02:39others in the coronary tree.
- 01:02:41So that's number one. And
- 01:02:42then the second big one
- 01:02:43is diabetes.
- 01:02:44So diabetic patients are more
- 01:02:46likely to have thin cap
- 01:02:47fibroathero.
- 01:02:48So those two situations
- 01:02:49raise your suspicion,
- 01:02:51in the individual patient.
- 01:02:53LV dysfunction, of course, if
- 01:02:54you have LV dysfunction because
- 01:02:55you had a priori,
- 01:02:57that not only makes it
- 01:02:58more likely that you do
- 01:02:59have latent thin cat fibroatheromas,
- 01:03:02but it also is more
- 01:03:03likely that the next rupture,
- 01:03:04of course, is gonna be
- 01:03:05fatal.
- 01:03:08So my question is even
- 01:03:09with this patient, many many
- 01:03:11of us would not send
- 01:03:13the patient to the cath
- 01:03:14lab. Right. Right? So you
- 01:03:16have symptoms. You're... You know,
- 01:03:17they're
- 01:03:18equivocal.
- 01:03:20So
- 01:03:21do you have any data
- 01:03:22on the role of CT
- 01:03:24angiography
- 01:03:25Yeah. And plaque characterization
- 01:03:27and outcomes from CTA? Yeah.
- 01:03:30So there is... And and
- 01:03:31and Jagged Arula, I think,
- 01:03:32has generated a lot of
- 01:03:33that work, and, there have
- 01:03:35been subsequent studies.
- 01:03:36They haven't done the types
- 01:03:38of prospective validation studies on
- 01:03:40a lesion specific level, but
- 01:03:42they have shown that that
- 01:03:44if you have low Hounsfeld
- 01:03:46unit plaques with positive remodeling,
- 01:03:48Okay? That... That's the classic
- 01:03:50two feature high risk plaques
- 01:03:51by CTA.
- 01:03:52The third one being the
- 01:03:53napkin ring sign is the
- 01:03:54most common,
- 01:03:56third predictor.
- 01:03:57That that does identify patients
- 01:03:59that are at future risk.
- 01:04:00Probably at the same lesions,
- 01:04:02but they just haven't done
- 01:04:03those studies.
- 01:04:04So... And especially, again, with
- 01:04:05the newer photon counting CT
- 01:04:07where, you know, the resolution's
- 01:04:08down to about two hundred
- 01:04:10microns, I think, is fair
- 01:04:11to say.
- 01:04:12You know, and the delineation
- 01:04:14you can get, you still
- 01:04:14can't see the thin fibrous
- 01:04:16cap, but it's getting really
- 01:04:17much better delineation for what
- 01:04:19is lipid versus calcium
- 01:04:21versus fibrotic plaque. And so,
- 01:04:23yeah, I think it is
- 01:04:24it is the screening test.
- 01:04:28So that was phenomenal
- 01:04:30talking because all of this
- 01:04:32came from you. We all
- 01:04:33believe every single word. No.
- 01:04:35No. Yeah. So Don't don't
- 01:04:37do that. Trying... I was
- 01:04:38trying to figure out what
- 01:04:39you were wanting us to
- 01:04:40say and answer the questions
- 01:04:42that way.
- 01:04:43But, you know, what you
- 01:04:45described is sort of
- 01:04:47good news because more information
- 01:04:48is always good news and
- 01:04:50bad news because if you
- 01:04:51do
- 01:04:52coronary angiograms
- 01:04:53or if you did
- 01:04:55OCT or
- 01:04:57spectroscopy,
- 01:04:59studies on a thousand people
- 01:05:01who you took off the
- 01:05:02street, you would probably find
- 01:05:04thin cap fibroatheomas
- 01:05:07in many, many of them.
- 01:05:08Right. So, you know, it
- 01:05:09almost raises the question, should
- 01:05:11this be like screening colonoscopies
- 01:05:13that everyone needs to get
- 01:05:15one of these Yeah. And
- 01:05:16be followed along serially because
- 01:05:18of that. And I I
- 01:05:19think that's
- 01:05:21maybe a little bit
- 01:05:22of a facetious question, but
- 01:05:24it it makes all of
- 01:05:25us probably nervous to to
- 01:05:27hear this lecture and to
- 01:05:28and to think about that.
- 01:05:30One of the things about
- 01:05:31medical therapy that I think
- 01:05:32we're... And,
- 01:05:33you know, you didn't talk
- 01:05:35about too much, but, you
- 01:05:36know, it's the inflammation part
- 01:05:38of this. Yeah. I can't
- 01:05:38help but but bring that
- 01:05:40up. I mean, I've been
- 01:05:40around long enough that
- 01:05:43the cholesterol people and the
- 01:05:44inflammation vascular biologists were arguing
- 01:05:47about what causes Yeah. Afterone.
- 01:05:49Clearly, it's both. Right. Right?
- 01:05:51And so PCSK nine inhibitors
- 01:05:53don't have those pleiotropic
- 01:05:55effects of Right. Anti inflammation
- 01:05:57that statins do. But do
- 01:05:58you wanna comment
- 01:06:00on any any Yeah. On
- 01:06:01sort of newer anti inflammatory
- 01:06:03therapies that might be
- 01:06:05Yeah. Well, I... And I'm
- 01:06:07a I'm a big believer
- 01:06:08in the inflammatory
- 01:06:09hypothesis as well.
- 01:06:11And, I mean, clearly, it
- 01:06:13can work. I mean, canakinumab
- 01:06:15worked, right, in the CANTOS
- 01:06:16trial.
- 01:06:18It it also led to
- 01:06:19fatal infections.
- 01:06:20But, you know, but inhibiting
- 01:06:22I l one, you know,
- 01:06:23which is very high upstream
- 01:06:24in the pathway worked. I
- 01:06:26think we were all really,
- 01:06:28disappointed
- 01:06:29when, you know, the last
- 01:06:31two negative trials have been
- 01:06:32released, and the IL six
- 01:06:33inhibitor did not work. We
- 01:06:35have... We'll see those results,
- 01:06:36I think, at the this
- 01:06:37year. But, we have to
- 01:06:39understand more, and we're still
- 01:06:40searching for where exactly in
- 01:06:42the inflammatory
- 01:06:43cascade do we interrupt that
- 01:06:44it is the right place.
- 01:06:46This all works through the
- 01:06:47NLRP three inflammasome,
- 01:06:49and so the question is
- 01:06:50how do we inhibit that
- 01:06:51from forming? And so I
- 01:06:52do think they're gonna get
- 01:06:54better and better at at
- 01:06:55finding the right drugs,
- 01:06:56you know,
- 01:06:57to interrupt inflammation.
- 01:06:59But I do think that
- 01:07:00what the,
- 01:07:01pharma community is doing wrong
- 01:07:03is they they wanna treat
- 01:07:05tens of millions of people.
- 01:07:07And so we're treating a
- 01:07:08lot of people that don't
- 01:07:09need to be treated. And
- 01:07:11so they're always gonna get
- 01:07:12these very small effect sizes
- 01:07:14because nine... If ninety percent
- 01:07:15of people don't need to
- 01:07:16be treated, they're just gonna
- 01:07:17dilute out all the benefit
- 01:07:18of the other patients who
- 01:07:19are having a marked benefit.
- 01:07:21That's why all the device
- 01:07:22trials always show these huge
- 01:07:24reductions
- 01:07:25in hazard ratios because they're
- 01:07:26only treating the very specific
- 01:07:28patients that need to be
- 01:07:29treated. It's not that devices
- 01:07:31are better than drugs. It's
- 01:07:32that we're treating the right
- 01:07:32patients.
- 01:07:37So, Greg, thank you so
- 01:07:38much for this incredible talk.
- 01:07:39And, I would like to
- 01:07:40touch upon your vision for
- 01:07:42the future, where you see
- 01:07:43that we're gonna be stenting
- 01:07:44those, you know, very mild
- 01:07:46lesions.
- 01:07:47And earlier today, we were
- 01:07:48discussing about most of the
- 01:07:50procedures are still angio guided.
- 01:07:52Right? So people don't use
- 01:07:53intravascular imaging very much. And
- 01:07:55you get situations like these
- 01:07:56where you have lesions close
- 01:07:57to the left main, so
- 01:07:58there will be angio guided
- 01:07:59procedures, you know, in different
- 01:08:02situations where stents are gonna
- 01:08:03be suboptimal implanted.
- 01:08:05Do you, are you concerned
- 01:08:06that we're gonna be trading
- 01:08:07the natural history risk
- 01:08:10with these more stent related,
- 01:08:12events
- 01:08:12somehow? Well, what you've seen,
- 01:08:14at least so far, the
- 01:08:15two randomized trials that have
- 01:08:17been done, and there have
- 01:08:18been... These are very soft
- 01:08:19lesions. They're very easy to
- 01:08:21treat with stents. And while
- 01:08:23the complications aren't gonna be
- 01:08:24zero and you're gonna occasionally
- 01:08:26get a restenosis,
- 01:08:28so far, they actually been
- 01:08:29in no stent thrombosis in
- 01:08:30either of the two trials.
- 01:08:31And you saw... I mean,
- 01:08:33so far, the overall MACE
- 01:08:34risk, which includes all those
- 01:08:36stent related events, seems like
- 01:08:38it might be substantially less
- 01:08:39than the natural history risk.
- 01:08:41But that's the trade off,
- 01:08:42to find the right lesions
- 01:08:43that have a high enough
- 01:08:44risk so that you can
- 01:08:46absorb some of the risk.
- 01:08:47Every procedure's got complications, so
- 01:08:48you can absorb some of
- 01:08:49those risks.
- 01:08:53Thanks so much, Erica Spatz.
- 01:08:54I'm a preventive cardiologist. So
- 01:08:56Good. Coming at it from
- 01:08:58the other way. So when,
- 01:09:00we... You know,
- 01:09:02a lot of us in
- 01:09:03the community looking at the
- 01:09:04PREVENT trial saw that a
- 01:09:06lot of the events were
- 01:09:07driven by nonacute events of
- 01:09:09revascularization
- 01:09:11and maybe out of jealousy
- 01:09:12that you guys did the
- 01:09:13outcomes trial first before we
- 01:09:14did the medical therapy one.
- 01:09:16But,
- 01:09:17what you were saying, you
- 01:09:19know, in terms of
- 01:09:20this vulnerable
- 01:09:22plaque is true for, you
- 01:09:23know, a vulnerable coronary tree.
- 01:09:25So it could be this,
- 01:09:26like, whack a mole situation
- 01:09:28where you identify one hot
- 01:09:30lesion, and then you got
- 01:09:31another one and another one.
- 01:09:33And,
- 01:09:34you know, what we've been
- 01:09:36thinking about is more of
- 01:09:37this residual risk.
- 01:09:39So what can we
- 01:09:41continually,
- 01:09:43modify
- 01:09:44with medications?
- 01:09:46What's left to be modified.
- 01:09:48And then, you know, so
- 01:09:49maybe there is sort of
- 01:09:50a
- 01:09:51a a strategy that, you
- 01:09:53know, puts people down a
- 01:09:54path where
- 01:09:56potentially PCI is that last
- 01:09:59resort when you still have
- 01:10:00these residual plaques that are
- 01:10:02high burden or in these,
- 01:10:03like, acute coronary situations where
- 01:10:05you're already in the... In
- 01:10:06there and you're looking at,
- 01:10:08you know, the the rest
- 01:10:09of the tree. So what
- 01:10:10are your thoughts on, you
- 01:10:11know, more of a strategic
- 01:10:13approach for more personalized care?
- 01:10:15So there's, like, three or
- 01:10:16four different different questions in
- 01:10:18there, so it's so it's
- 01:10:19great.
- 01:10:21So first of all, the
- 01:10:22one thing that we don't
- 01:10:23know about drug therapy, I
- 01:10:25showed you some of the
- 01:10:25mechanistic studies that were done,
- 01:10:27the four randomized trials.
- 01:10:29Those were also... Always done
- 01:10:31on mild to moderate plaques.
- 01:10:33Okay? We don't know if
- 01:10:34once you have a well
- 01:10:36formed vulnerable plaque that's more
- 01:10:37than seventy percent plaque burden
- 01:10:39with a thin fibrous cap
- 01:10:40and a lot of lipid,
- 01:10:41we don't know if the
- 01:10:43drugs will act fast enough
- 01:10:44to be able to stabilize
- 01:10:46those. So that's one question.
- 01:10:48The second thing is what
- 01:10:49you say is absolutely very
- 01:10:50true about whack a mole
- 01:10:52to some extent.
- 01:10:54But we've seen that for
- 01:10:56about three to four years,
- 01:10:58it takes several
- 01:10:59years. These lesions do change
- 01:11:01morphology, but it takes several
- 01:11:03years for that to happen.
- 01:11:04So if you take care
- 01:11:05of, quote, the tiktvas
- 01:11:07at time zero, as you
- 01:11:09see, you're probably pretty good
- 01:11:11for about three to four
- 01:11:12years. And then if you
- 01:11:13can then give your preventative
- 01:11:15background therapy so you don't
- 01:11:16get new ones developed,
- 01:11:18you know, then you're probably
- 01:11:19in good shape. So I
- 01:11:20think these are more complementary
- 01:11:21approaches rather than, competitive approaches.
- 01:11:24The third thing, and perhaps
- 01:11:25most complicated aspect though, is
- 01:11:27how do you find these
- 01:11:29things? I mean,
- 01:11:30you've got, again, you know,
- 01:11:32as you mentioned, you know,
- 01:11:33the the walking well that
- 01:11:34don't know they're walking around
- 01:11:36with them. But those patients
- 01:11:37have, the average person, very
- 01:11:39low levels of inflammation,
- 01:11:41and their per year risk
- 01:11:42is probably quite small,
- 01:11:45patients who are asymptomatic
- 01:11:46or have non cardiac symptoms.
- 01:11:48So for those patients, I
- 01:11:50like the Braunwald algorithm. Let's
- 01:11:52identify the ones with a
- 01:11:53lot of risk factors that
- 01:11:54are more likely to have
- 01:11:55them, perhaps use CRP or
- 01:11:57other, test to screen for
- 01:11:59inflammation,
- 01:11:59and then go down a
- 01:12:01more noninvasive and invasive screening
- 01:12:03category that ultimately applies to
- 01:12:05five percent or ten percent
- 01:12:06of the population at most.
- 01:12:08But if you're in the
- 01:12:09lab with a patient with
- 01:12:10an acute coronary syndrome,
- 01:12:12on average, from from all
- 01:12:13of our studies, once you
- 01:12:14present with an MI,
- 01:12:16you've got another four and
- 01:12:17a half lesions on average
- 01:12:19throughout the coronary tree. And
- 01:12:21one to two of those
- 01:12:23on average are thin cap
- 01:12:24fibroatheromas.
- 01:12:26So maybe then and there,
- 01:12:27you should be treating them
- 01:12:28the way we'd complete
- 01:12:30the trial. We're now treating
- 01:12:31all the seventy percent stenoses.
- 01:12:33If we can identify the
- 01:12:34ones that are... That really
- 01:12:35need the treatment, it's not
- 01:12:36the seventy percent stenosis, but
- 01:12:38you're leaving behind half of
- 01:12:39the others that need to
- 01:12:40be treated as well. So
- 01:12:42I think there's complimentary ways
- 01:12:43to work all of this
- 01:12:44into the best management.
- 01:12:46To ask a question, David.
- 01:13:00Thank you very much.
- 01:13:03Right. Thank you. Wonderful talk.
- 01:13:05I'm wondering the, collagen content
- 01:13:08decide the cap, sing, or
- 01:13:10stick. So, typically, the synthetic
- 01:13:14produce a collagen Yeah. To
- 01:13:15stabilize. What do you think
- 01:13:17about all kinds of therapy?
- 01:13:18Could you stabilize the cap
- 01:13:20smooth muscle cell under
- 01:13:21synthetic step
- 01:13:23or,
- 01:13:24contractor or, like, a smooth
- 01:13:25muscle cell toward macrophage, which
- 01:13:27may degrade the collagen? What
- 01:13:29are thoughts about, the root
- 01:13:30issue of this thin thick
- 01:13:32cap? Yeah. Wait. Wait. Yeah.
- 01:13:34Absolutely. I mean, there may
- 01:13:35be newer therapies that can
- 01:13:37do that, and it's not
- 01:13:38normal. Even though it's thin,
- 01:13:40what... It is thin, but
- 01:13:41it's not only thin. It's
- 01:13:43also abnormal collagen. So if
- 01:13:44type one collagen is replaced
- 01:13:46by type three collagen in
- 01:13:47addition to all the inflammation
- 01:13:49going on in the cap.
- 01:13:50So, yeah, it is possible
- 01:13:51that there... You know? And
- 01:13:52and there are targeted therapies
- 01:13:54that are being worked on
- 01:13:55for the extracellular matrix to
- 01:13:57thicken the cap and to
- 01:13:58stabilize the cap in other
- 01:13:59ways.
- 01:14:02Excellent talk. I really enjoyed
- 01:14:03your talk. And Thank you.
- 01:14:04My question is that you
- 01:14:05started your talk by saying
- 01:14:06that we have a high
- 01:14:07rate of mortality.
- 01:14:08And now you... What you
- 01:14:10presented, obviously, mace is reduced.
- 01:14:12The question is that do
- 01:14:13we reduce the mortality? And,
- 01:14:15you know, the cabbage which
- 01:14:16bypasses all this has not
- 01:14:18shown to be actually reducing
- 01:14:19mortality. Now, Erica mentioned actually
- 01:14:21the residual
- 01:14:23risk, and we talked about,
- 01:14:24lack of Except for in
- 01:14:26stitch. Except for in stitch.
- 01:14:30They, like, opened a little
- 01:14:31aid. I'd unfortunately wanna trial
- 01:14:33failed, but I think that
- 01:14:35that is kind of, what
- 01:14:37are your thoughts about what
- 01:14:38to do to actually reduce
- 01:14:39really mortality?
- 01:14:41I mean, now, actually, I
- 01:14:42wanna also mention something that
- 01:14:43we haven't published yet, but
- 01:14:44I wanna actually kind of
- 01:14:45make some people aware here
- 01:14:47that you reduce the plasma
- 01:14:49cholesterol,
- 01:14:50but a lot of,
- 01:14:51based on genetic study, a
- 01:14:53lot of diseases that actually
- 01:14:55increase the cholesterol within the
- 01:14:56cell because the cholesterol in
- 01:14:58the plasma is reduced. You
- 01:14:59take it up, but then
- 01:15:01it's gonna go to the
- 01:15:01wrong places such as lysosomes
- 01:15:03and then causes inflammation but
- 01:15:04whatnot. And my question to
- 01:15:07you is that is the
- 01:15:07intervention gonna do the job
- 01:15:09for reducing mortality or medical
- 01:15:11therapy?
- 01:15:12Yeah. So so I think
- 01:15:13if we can prevent these
- 01:15:14things from rupturing in thrombosis...
- 01:15:17Thrombosing,
- 01:15:18then we will prevent myocardial
- 01:15:19infarctions, and that will prevent
- 01:15:21mortality.
- 01:15:23So I I totally agree
- 01:15:24with you. It's it's fine
- 01:15:25to say we can reduce
- 01:15:27MACE.
- 01:15:27And, yes, the unstable angina
- 01:15:29and unplanned hospitalization,
- 01:15:32you know, that's a a
- 01:15:33very unpleasant event. Patients don't
- 01:15:35want to have that. That's
- 01:15:36a good thing to prevent.
- 01:15:37But, yeah, we'd like to
- 01:15:38have definite, you know, medical
- 01:15:39evidence that we're reducing CV
- 01:15:40death and MI to
- 01:15:42start. And of all the...
- 01:15:44But this becomes a statistics
- 01:15:45game. Okay? So, you know,
- 01:15:47when you're in relatively healthy
- 01:15:49populations that have good background
- 01:15:51treatments, their rates are relatively
- 01:15:53low. So of all those
- 01:15:54trials I showed you, the
- 01:15:55one that we're running in
- 01:15:56China at, thirty one hundred
- 01:15:58and thirty patients is the
- 01:15:59only one that's powered for
- 01:16:01a reduction in cardiovascular death
- 01:16:02or myocardial infarction.
- 01:16:04To show a reduction in
- 01:16:06cardiovascular
- 01:16:07death or all cause death,
- 01:16:08you would need over ten
- 01:16:09thousand
- 01:16:11patients. And so pharma does
- 01:16:12that all the time, but
- 01:16:13they don't do that in
- 01:16:15targeted vulnerable plaque populations.
- 01:16:17So I don't see that
- 01:16:19size trial happening in an
- 01:16:20interventional trial soon in this
- 01:16:22field because of the need
- 01:16:23for imaging. But I think
- 01:16:25that if we can show
- 01:16:25a reduction in CV death
- 01:16:27or MI, that that will
- 01:16:28be convincing to most people.
- 01:16:30With that, let me again
- 01:16:32thank Greg for joining us.
- 01:16:34Wonderful talk. Thank you. Thanks,.